Pfizer Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Meenakshi Nevatia

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.1yrs
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	7.2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Meenakshi Nevatia (52 yo)

1.1yrs

Permanencia

Mrs. Meenakshi Nevatia serves as Non-Executive Independent Director at TeamLease Services Ltd. since July 28, 2021. Mrs. Nevatia is the Managing Director of Stryker India since October 2018.She has focuse...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Meenakshi Nevatia	MD & CEO	1.1yrs	sin datos	sin datos
Amit Agarwal	Executive Director of Finance	less than a year	sin datos	sin datos
Anil Pattanshetty	Senior Director of Business Operations	no data	sin datos	sin datos
Prajeet Nair	Director of Corporate Services	16.7yrs	₹5.22m	sin datos
Sharad Goswami	Senior Director of Policy & Public Affairs	no data	sin datos	sin datos
Shilpi Singh	Director of People Experience	no data	sin datos	sin datos
Chaitanya Nadkarni	India Digital Client Partner Lead	less than a year	sin datos	sin datos

0.9yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 500680 no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Meenakshi Nevatia	MD & CEO	1.1yrs	sin datos	sin datos
Amit Agarwal	Executive Director of Finance	less than a year	sin datos	sin datos
Meena Ganesh	Independent Woman Director	5.2yrs	₹2.23m	sin datos
Sunil Lalbhai	Non Executive Independent Director	9.3yrs	₹2.37m	0.0054% ₹ 10.4m
Pradip Shah	Non-Executive Independent Chairman of the Board	24.4yrs	₹2.49m	sin datos
Uday Khanna	Non Executive Independent Director	12yrs	₹2.40m	sin datos

7.2yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 500680 se considera experimentada (7.1 años de antigüedad promedio).

Pfizer Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023

Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023

Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors

Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead

Recent updates

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023)

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024

Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023

Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023

Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors

Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023)

Pfizer Limited to Report Q2, 2024 Results on Oct 28, 2023

Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead

Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023

New major risk - Revenue and earnings growth

Pfizer Limited Announces Change in Management, Effective September 1, 2023

Pfizer Limited to Report Q1, 2024 Results on Aug 11, 2023

Upcoming dividend of ₹40.00 per share at 0.9% yield

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited, Annual General Meeting, Aug 18, 2023

Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023

Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections

Price target decreased by 7.9% to ₹4,595

Pfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited to Report Fiscal Year 2023 Results on May 15, 2023

Third quarter 2023 earnings released: EPS: ₹32.93 (vs ₹31.46 in 3Q 2022)

Pfizer India Appoints Meenakshi Nevatia as CEO

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Upcoming dividend of ₹30.00 per share

Pfizer Limited Announces Interim (Special) Dividend for the Financial Year Ending March 31, 2023, Payable on or Before September 30, 2022

Pfizer Limited Approves Declaration of Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹35.00 per share

Pfizer Announces Resignation of S. Sridhar as Managing Director

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

Mylan Pharmaceuticals Private Limited completed the acquisition of off-patent branded and generic established medicines business from Pfizer Limited (BSE:500680).

Pfizer Limited to Report Q1, 2023 Results on Aug 05, 2022

Now 20% undervalued after recent price drop

Price target decreased to ₹5,201

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₹134 (vs ₹109 in FY 2021)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2022, Payable on or before September 23, 2022

Price target decreased to ₹5,654

Insufficient new directors

Insufficient new directors

Pfizer and FDA Dropped Data Bombshell on Covid Vaccine Consumers

Price target decreased to ₹5,749

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Pfizer Limited Announces Board Changes

Pfizer Limited Announces Resignation of R. A. Shah as an Independent Director

Second quarter 2022 earnings released: EPS ₹31.25 (vs ₹28.71 in 2Q 2021)

Upcoming dividend of ₹35.00 per share

Price target increased to ₹6,099

Price target increased to ₹5,945

First quarter 2022 earnings released: EPS ₹43.69 (vs ₹27.20 in 1Q 2021)

Full year 2021 earnings released: EPS ₹109 (vs ₹111 in FY 2020)

Pfizer Limited Recommends Normal Dividend for the Year Ended March 31, 2021, Payable on or Before September 15, 2021

GlobalSpace Technologies Limited Announces Strategic Partnership with Pfizer

New 90-day low: ₹4,464

Third quarter 2021 earnings released: EPS ₹30.87 (vs ₹30.40 in 3Q 2020)

New 90-day low: ₹4,862

New 90-day high: ₹5,338

New 90-day high: ₹5,203

Second quarter 2021 earnings released: EPS ₹28.71

New 90-day high: ₹5,062

Pfizer Limited to Report Q3, 2021 Results on Feb 14, 2021

New 90-day high - ₹4,857